Pfizer Inc. — 2014 Form 10-K Summary
Business context and reporting period
Pfizer is a global research-based biopharmaceutical company. This annual report covers the fiscal year ended December 31, 2014; it is not a standalone fourth-quarter report. In 2014, Pfizer reorganized commercial operations into three segments: Global Innovative Pharmaceutical (GIP), Global Vaccines, Oncology and Consumer Healthcare (VOC), and Global Established Pharmaceutical (GEP).
Financial and operating metrics
| Metric | 2014 information disclosed in the supplied filing text |
|---|---|
| Biopharmaceutical revenue | $45.7 billion, down 5% from 2013: operational revenues declined 3%, and foreign exchange reduced revenue 2%. |
| Consumer Healthcare revenue | $3.4 billion, up 3%; operational growth of 5% was partly offset by a 2% foreign-exchange impact. |
| Research and development | $8.4 billion, compared with $6.7 billion in 2013 and $7.5 billion in 2012. |
| International operations | $30.5 billion of revenue, equal to 62% of total revenue. The U.S. represented 38% of total revenue. |
| Share repurchases | 40.0 million shares purchased under the publicly announced plan in Q4 at an average $29.94 per share; approximately $11.516 billion remained available under the plan at year-end. |
The supplied text refers readers to the 2014 Financial Report for consolidated statements and detailed MD&A, but does not provide clear consolidated revenue, net income, cash flow, margin, debt, or liquidity values. It also does not provide the specific 2015 financial guidance figures.
Material changes versus prior periods
- Biopharmaceutical revenue fell 5% year over year. U.S. biopharmaceutical revenue decreased 8%; international biopharmaceutical revenue decreased 3%, primarily reflecting foreign exchange.
- Consumer Healthcare revenue increased 3% year over year.
- R&D spending increased from $6.7 billion in 2013 to $8.4 billion in 2014.
- Pfizer adopted a new global commercial structure in 2014; segment comparisons were conformed to the new structure.
- Generic versions of Celebrex became available in the U.S. in December 2014 under settlement agreements, and Pfizer identified further near-term generic competition for other products.
Outlook, risks, contingencies, and unusual items
- On February 5, 2015, after the fiscal year-end, Pfizer agreed to acquire Hospira for $90 per share in cash, with an approximate enterprise value of $17 billion. Closing was expected in the second half of 2015, subject to shareholder and regulatory approvals and other conditions.
- Management identifies pricing and reimbursement pressure, generic and biosimilar competition, patent challenges and expirations, foreign-exchange movements, R&D and regulatory uncertainty, and reliance on key products as significant risks.
- Ten biopharmaceutical products each generated more than $1 billion in direct product revenue and together represented 54% of biopharmaceutical revenue, creating meaningful concentration in key brands.
- Pfizer reported no serious raw-material shortages or delays in 2014 and expected none in 2015. Environmental expenditures included $19 million of capital spending and $160 million of other expenses.
- The filing discusses litigation, investigations, environmental liabilities, and potential transaction and integration costs. The supplied text does not state a clear aggregate contingency amount.
Most important facts for investors to verify
- Review the incorporated 2014 Financial Report for consolidated revenue, earnings, cash flows, balance-sheet liquidity, debt, margins, and the full 2015 guidance.
- Assess the drivers of the 5% biopharmaceutical revenue decline and the outlook for products facing patent loss or generic competition, particularly Celebrex.
- Check the Hospira acquisition’s final approval status, financing, purchase accounting, integration costs, and realized benefits.
- Review the detailed segment results, restructuring and productivity costs, and material legal and tax contingencies.
- Evaluate capital allocation, including dividends, repurchases, and the remaining share-buyback authorization.